Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 5 | 2022 | 24 | 1.830 |
Why?
|
| Cerebellar Neoplasms | 2 | 2022 | 17 | 1.050 |
Why?
|
| Brain Neoplasms | 4 | 2022 | 371 | 0.880 |
Why?
|
| Casein Kinase Ialpha | 3 | 2018 | 3 | 0.830 |
Why?
|
| Benzoates | 2 | 2018 | 20 | 0.790 |
Why?
|
| Melatonin | 9 | 2020 | 39 | 0.750 |
Why?
|
| Smoothened Receptor | 3 | 2022 | 10 | 0.740 |
Why?
|
| Hedgehog Proteins | 6 | 2022 | 38 | 0.700 |
Why?
|
| Signal Transduction | 14 | 2022 | 2689 | 0.650 |
Why?
|
| Zinc Finger Protein GLI1 | 6 | 2022 | 13 | 0.500 |
Why?
|
| Neurons | 6 | 2019 | 881 | 0.380 |
Why?
|
| Oxidative Stress | 3 | 2008 | 718 | 0.330 |
Why?
|
| Oxidopamine | 1 | 2008 | 42 | 0.320 |
Why?
|
| Nerve Degeneration | 2 | 2008 | 134 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.290 |
Why?
|
| Glioma | 4 | 2009 | 140 | 0.270 |
Why?
|
| Dopamine | 1 | 2008 | 474 | 0.260 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1174 | 0.250 |
Why?
|
| Apoptosis | 5 | 2013 | 1641 | 0.220 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2022 | 20 | 0.210 |
Why?
|
| Antioxidants | 5 | 2007 | 304 | 0.200 |
Why?
|
| Pyridines | 2 | 2018 | 261 | 0.190 |
Why?
|
| Transcription Factors | 4 | 2019 | 753 | 0.190 |
Why?
|
| Animals | 17 | 2020 | 20881 | 0.180 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 306 | 0.180 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2020 | 21 | 0.180 |
Why?
|
| Nuclear Proteins | 2 | 2019 | 271 | 0.180 |
Why?
|
| Mice | 9 | 2020 | 8474 | 0.170 |
Why?
|
| Cerebellar Cortex | 1 | 2019 | 4 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 446 | 0.170 |
Why?
|
| Cerebellar Ataxia | 1 | 2019 | 8 | 0.170 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 32 | 0.170 |
Why?
|
| Neurogenesis | 1 | 2019 | 32 | 0.170 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 6 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 116 | 0.160 |
Why?
|
| Anilides | 1 | 2018 | 16 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 163 | 0.160 |
Why?
|
| Heterografts | 1 | 2018 | 70 | 0.160 |
Why?
|
| Pyrvinium Compounds | 2 | 2017 | 2 | 0.160 |
Why?
|
| Glucose | 1 | 2020 | 307 | 0.160 |
Why?
|
| Enzyme Activators | 1 | 2017 | 14 | 0.150 |
Why?
|
| Wnt Proteins | 1 | 2017 | 57 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 231 | 0.140 |
Why?
|
| Cell Cycle | 4 | 2019 | 312 | 0.140 |
Why?
|
| Mice, Nude | 5 | 2017 | 294 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2014 | 167 | 0.130 |
Why?
|
| Cell Differentiation | 3 | 2020 | 1034 | 0.120 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 34 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2550 | 0.120 |
Why?
|
| Humans | 15 | 2022 | 68618 | 0.120 |
Why?
|
| Hippocampus | 3 | 2007 | 471 | 0.120 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 1851 | 0.120 |
Why?
|
| Neoplasms | 2 | 2017 | 1667 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2009 | 331 | 0.120 |
Why?
|
| Neuroprotective Agents | 2 | 2007 | 317 | 0.110 |
Why?
|
| Cell Death | 3 | 2008 | 329 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 756 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 138 | 0.100 |
Why?
|
| Child | 1 | 2022 | 6405 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 1745 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2008 | 97 | 0.090 |
Why?
|
| Caspases | 2 | 2008 | 194 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 235 | 0.090 |
Why?
|
| Rats | 6 | 2008 | 5300 | 0.090 |
Why?
|
| Protein Kinase C | 2 | 2009 | 270 | 0.090 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 26 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1070 | 0.090 |
Why?
|
| Brain | 2 | 2018 | 2176 | 0.080 |
Why?
|
| Cell Line | 5 | 2014 | 1752 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 65 | 0.080 |
Why?
|
| Reactive Oxygen Species | 3 | 2007 | 499 | 0.080 |
Why?
|
| Genes, cdc | 1 | 2008 | 5 | 0.080 |
Why?
|
| Sympatholytics | 1 | 2008 | 11 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 2 | 2007 | 102 | 0.080 |
Why?
|
| PC12 Cells | 1 | 2008 | 36 | 0.080 |
Why?
|
| Neurotoxins | 1 | 2008 | 30 | 0.080 |
Why?
|
| Cyclin D1 | 1 | 2008 | 37 | 0.080 |
Why?
|
| Phosphorylation | 3 | 2019 | 1200 | 0.080 |
Why?
|
| Retinoblastoma Protein | 1 | 2008 | 75 | 0.080 |
Why?
|
| Mitosis | 1 | 2008 | 76 | 0.080 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 300 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2008 | 102 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 304 | 0.080 |
Why?
|
| Cell Survival | 3 | 2020 | 901 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 247 | 0.070 |
Why?
|
| Glutathione | 2 | 2007 | 343 | 0.070 |
Why?
|
| Tryptamines | 1 | 2006 | 7 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 468 | 0.070 |
Why?
|
| Neuroglia | 1 | 2006 | 136 | 0.070 |
Why?
|
| Sesquiterpenes | 1 | 2005 | 41 | 0.060 |
Why?
|
| Parkinson Disease | 1 | 2008 | 272 | 0.060 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2020 | 67 | 0.060 |
Why?
|
| Autophagy | 1 | 2006 | 208 | 0.060 |
Why?
|
| Acetylcysteine | 1 | 2007 | 296 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2022 | 18 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 1692 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1173 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 89 | 0.050 |
Why?
|
| Mitochondria | 1 | 2007 | 643 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2017 | 791 | 0.050 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2020 | 1 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 71 | 0.040 |
Why?
|
| Casein Kinase Idelta | 1 | 2019 | 1 | 0.040 |
Why?
|
| Oxidation-Reduction | 3 | 2006 | 567 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 86 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 56 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2019 | 396 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2019 | 447 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2010 | 233 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 63 | 0.040 |
Why?
|
| Xenopus laevis | 1 | 2017 | 60 | 0.040 |
Why?
|
| Surface Plasmon Resonance | 1 | 2017 | 50 | 0.040 |
Why?
|
| Organ Culture Techniques | 1 | 2017 | 122 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 57 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2007 | 127 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 532 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 150 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 147 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2673 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 25 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 35 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 65 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2007 | 432 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 40 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2014 | 176 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 266 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2014 | 183 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2014 | 237 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 710 | 0.030 |
Why?
|
| Glutamic Acid | 2 | 2007 | 332 | 0.030 |
Why?
|
| Ligands | 1 | 2012 | 317 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 122 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 2791 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2010 | 5 | 0.020 |
Why?
|
| Vincristine | 1 | 2010 | 44 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 498 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 64 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 57 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2014 | 902 | 0.020 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 19 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 40 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 88 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 260 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 114 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 174 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 981 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 489 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2007 | 37 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 954 | 0.020 |
Why?
|
| Serotonin Agents | 1 | 2006 | 13 | 0.020 |
Why?
|
| Cytoplasmic Structures | 1 | 2006 | 8 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 85 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 128 | 0.020 |
Why?
|
| Serotonin | 1 | 2006 | 144 | 0.020 |
Why?
|
| Free Radicals | 1 | 2006 | 65 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 2005 | 24 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 371 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 305 | 0.020 |
Why?
|
| Chromans | 1 | 2004 | 12 | 0.020 |
Why?
|
| Ferrous Compounds | 1 | 2004 | 18 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2004 | 94 | 0.020 |
Why?
|
| Female | 2 | 2020 | 38074 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2007 | 682 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 852 | 0.010 |
Why?
|
| Astrocytes | 1 | 2006 | 270 | 0.010 |
Why?
|
| Homeostasis | 1 | 2005 | 291 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 420 | 0.010 |
Why?
|
| Estradiol | 1 | 2004 | 176 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 474 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1118 | 0.010 |
Why?
|
| Male | 1 | 2004 | 37321 | 0.000 |
Why?
|
Rodriguez-Blanco's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_